Evolus Inc., a performance beauty company, has announced a partnership with Symatese to distribute Nuceiva® (botulinum toxin type A) in France. This move is part of Evolus's geographic expansion strategy, aiming to deliver its aesthetic solutions to the French market. Nuceiva®, known as Jeuveau® in the United States, has been the fastest-growing neurotoxin there for four consecutive years. The product is approved for improving the appearance of severe glabellar lines in adults below 65. The collaboration with Symatese, a well-established French firm in the aesthetics industry, will facilitate direct order and delivery of Nuceiva® to healthcare professionals in France, marking a significant step in Evolus's global growth strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.